Selected Publications by Medaffcon Oy
These articles, posters and study abstracts represent a subset of the biobank and other real world evidence -based studies conducted by Medaffcon.
Peer-reviewed articles
Heart failure in Finland: clinical characteristics, mortality, and healthcare resource use, Huusko J, Kurki S, Toppila I, Purmoen T, Lassenius M, Gullberg E, Bruce-Wirta S, Ukkonen H. ESC Heart Failure 2019(2019). DOI: 10.1002/ehf2.12443.
Burden of migraine in Finland: health care resource use, sick-leaves and comorbidities in occupational health care, Korolainen M, Kurki S, Lassenius M, Toppila I, Costa-Scharplatz M, Purmonen T and Nissilä M. (2019) 20:13: Journal of headache and pain, DOI 10.1186/s10194-019-0964-5. https://rdcu.be/bmtGA
Type 2 diabetes and treatment intensification in primary care in Finland, Niskanen L, Hahl J, Haukka J, Leppä E, Miettinen T, Mushnikov V, Sipilä R, Tamminen N, Vattulainen P and Korhonen P. Acta Diabetologica 2018;55:1171–1179.
Health care resource utilization and characteristics of patients with eosinophilic asthma in secondary health care in Finland. Mäkelä MJ, Christensen HN, Karlsson A, Rastogi S, Kettunen K. Eur Clin Respir J. 2018; 5(1):1458560.
The economic burden of severe eosinophilic asthma for health care in Finland. Manuscript in preparation.
The economic burden of severe COPD for health care in Finland. Manuscript in preparation.
Indirect and direct costs of cardiovascular disease related primary prevention and secondary prevention. Manuscript in preparation.
Posters or oral presentations at international congresses
Study to determine predictive potential of an algorithm for earlier diagnosis of Gaucher disease: Retrospective biobank study utilizing real-world data available in Finland. Savolainen M, Karlsson A, Toppila I, Elomaa K, Panahloo Z, Wolf M. 15th Annual WORLD Symposium; Feb 4-8, 2019; Orlando, Florida, USA.
Health Registry Data Survey for Assessing Characteristics and Descriptive Epidemiology of Patients with Multiple Myeloma in Southwest Finland between 2004—May 2017. Salmi T, Saukkonen K, Wolf, M, Toppila I, Kurki S, Schoonen M, Putkonen M. ESH, 4th International Conference on multiple myeloma, Oct 5-7, 2018, Mandelieu, France.
Health care resource use, sick-leaves and comorbidities among migraine patients in occupational healthcare. Minna A. Korolainen, Samu Kurki, Iiro Toppila, Mariann Lassenius, Timo Purmonen and Markku Nissilä. European Head Ache federation meeting, Florence Italy 28-30.9.2018
Heart Failure in Finland – Evaluating the burden of disease and treatment patterns. J Huusko, S Kurki, I Toppila, T Purmonen, M Lassenius, E Gullberg, S Bruce Wirta, H Ukkonen. European Society of Cardiology Congress 2018 in Munich, Germany
Trend towards longer time to reimbursement in oncological medicines in Finland 2005-2015. Oinonen L, Renlund M, Pudas H, Ihalmo P, Hahl J. ISPOR 2016.
The epidemiology of adult immune (idiopathic) thrombocytopenic purpura (ITP) in Finland: resource utilisation, related costs and hospital medication associated with the treatment of non-splenectomised adult ITP based on real world data from Auria biobank. Kosunen M, Kurki S, Snicker K, Wiik E. ISPOR 2017
Resource utilisation and related health care costs among patients with multiple myeloma with ≥ 2 prior lines of treatment in Finland: evaluation based on Finnish real world data from Auria biobank. Kosunen M, Kurki S, Snicker K, Wiik E. ISPOR 2017
Resource use, health care costs and burden of disease in patients with polycythemia vera in Finland: evaluation based on leukocyte counts using Finnish real world data from Auria biobank. Kosunen M, Kurki S, Snicker K, Wiik E. ISPOR 2017.
Cost-effectiveness of Pasireotide long-acting in a treatment of acromegaly in Finland economic evaluation based on Finnish Auria biobank data on health care resource utilization. Hahl J, Kurki S, Miettinen T, Snicker K. ISPOR 2017.
Other
Tutkimuksen uudet mahdollisuudet on huomioitava biopankkilaissa. Tuompo W, Hemmilä P, Ahlamaa J, Wolf M. Finnish Medical Journal 2018;37(2006-2007).
Selected Biobank Study Abstracts
Study to determine predictive potential of an algorithm for earlier diagnosis of Gaucher disease, utilizing linkage to Auria biobank samples in Finland (SPOT-GD -study), Shire Finland Oy
Gaucher disease (GD) is a lysosomal storage disease, caused by deficiency of the enzyme β-glucocerebrosidase. This leads to accumulation of glucosylceramide in reticuloendothelial cells of spleen, bone marrow and liver. Delay in GD diagnostics is a major challenge and can lead to dysfunction and damages of the target organs. The international Gaucher Earlier Diagnosis Consensus (GED-C) initiative has established a point-scoring system for clinical parameters to promote earlier diagnosis of the disease. The aim of this study was to locally adjust and apply the point-scoring system to health record data available in Auria Biobank, and by using this approach, identify potential undiagnosed patients with Gaucher disease.
A biobank and health register analysis of burden of disease in severe asthma or COPD patients, GSK Finland
This study surveys the status and characteristics of patients with severe asthma or COPD, diagnosed in the hospital district of Southwest Finland during 2004-2015. Information regarding treatment, health care resource use and associated costs, as well as mortality will be explored.
Clinical characteristics of the Multiple Myeloma patient cohort diagnosed in Southwest Finland during 2004-2017, Amgen AB Finland
Multiple myeloma (MM) is the second most common hematological cancer representing 10-15% of all hematological malignancies. MM results from the clonal expansion of monoclonal plasma cells in the bone marrow, leading to increased secretion of abnormal immunoglobulin into urine and / or peripheral blood. Overproduction of the immunoglobulin fragment causes several deleterious systemic effects, leading to symptoms typically affecting bones and renal function. While MM still remains mostly incurable, the overall survival of MM patients has improved significantly due to the development of more effective therapies.
The special characteristics of chronic lymphocytic leukaemia in the Hospital District of Southwest Finland in 2004–2013, AbbVie
Chronic lymphocytic leukaemia (CLL) is the most common haematological cancer in Western countries. It is typically found as a coincidental finding in connection with other examinations. While asymptomatic CLL typically is not treated, commonly used treatment options in the most difficult forms of the disease include chemoimmunotherapy and other new cancer-specific drugs. The treatment of CLL has developed immensely during the past ten years and therefore the prognosis has improved in all variants of the disease. This study determines the current situation of CLL, e.g. characteristics of the patient population, used treatment regiments and associated outcomes. With the information obtained, it will be possible to evaluate treatments needed in the future and how much resources they require from the healthcare.
Examining the epidemiology, treatment, comorbidites and prognosis of rare immunological haematological diseases in the Hospital District of Southwest Finland in 2003–2014, Novartis Finland Oy
Chronic immunological thrombocytopenic purpura (ITP) and aplastic anaemia (AA) are rare autoimmune-based blood disorders. The exact causes of these diseases are not fully known. The prognosis of aplastic anaemia, in particular, was very poor 40 years ago as estimated survival of a patient with serious AA was only 1–2 years from the diagnosis. This study examines the prevalence, prognosis and complications of ITP and AA, related costs and treatments used. The study provides also valuable information of the impact of the treatments on prognosis of the patients.
